IN VIVO LUNG PERFUSION (IVLP) AS AN ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE OR UNRESECTABLE PULMONARY METASTASES OF COLORECTAL CARCINOMAS
- Registry ID
- 20-6152
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- UNIVERSITY HEALTH NETWORK
- Start date
- 2023-05-01
- Last update
- 2021-02-24
Conditions
- COLORECTAL CARCINOMA
- METASTATIC CANCERS
Related clinical trials
- A PHASE 1/2, MULTICENTER, OPEN LABEL, DOSE ESCALATION & DOSE EXPANSION STUDY OF JK06, A 5T4 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER
- A PHASE 1A/1B, FIRST-IN-HUMAN, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF
RGT-61159 FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY ADENOID CYSTIC CARCINOMA
(ACC) OR COLORECTAL CARCINOMA (CRC)
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA
- A PHASE 1/2A TWO-PART, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF OC-001 AS MONOTHERAPY AND IN COMBINATION WITH AN ANTI-PD-L1 ANTIBODY IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS
- PHASE 1 STUDY OF ZW49 IN PATIENTS WITH LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC HER2-EXPRESSING CANCERS
- PHASE 1 TRIAL OF ZW25 IN PATIENTS WITH LOCALLY ADVANCED (UNRESECTABLE) AND/OR METASTATIC HER2-EXPRESSING CANCERS
View on source registry